Jonathan Boyers

Managing Director
35+ years of experience in corporate finance
Advises on company disposals, acquisitions and private equity
Head of A&M’s Corporate Finance practice in EMEA
London
@alvarezmarsal
LinkedIn
Copied!
Jonathan Boyers is a Managing Director and Head of Alvarez & Marsal’s Corporate Finance practice in EMEA.

With more than 35 years of experience in corporate finance, Mr. Boyers has advised a variety of clients in respect to company disposals, acquisitions and private equity work across a wide range of industries. He has advised hundreds of companies and entrepreneurs regarding strategy and corporate finance transactions, with deal sizes ranging from £10 million to £500 million.

Prior to joining A&M, Mr. Boyers spent 32 years in Corporate Finance at KPMG, most recently serving as Partner. Previously at KPMG, he was the UK Head of Corporate Finance, leading that business through its most successful trading period ever. Mr. Boyers was also a Vice Chair of KPMG in the U.K.

Mr. Boyers earned a bachelor’s degree in accounting and finance (first class) from the University of Lancaster. He has won North West Insider Magazine Dealmaker of the Year four times and was awarded the “UK Corporate Financier of the Year” award by the Institute of Chartered Accountants of England and Wales.

Insights By This Professional

Jan Crosby joins A&M’s Corporate Finance practice in London to expand its Real Estate and Hospitality capability across Europe.
Das Schweizer Corporate-Finance-Team von A&M unter der Leitung von Stephan Brücher, Managing Director, wird seine Dienstleistungen ab April 2025 als Teil von A&M anbieten
The Swiss A&M corporate finance team, led by Stephan Brücher, Managing Director, will begin offering its services to clients as part of A&M in April 2025.
Die neue Business Unit ergänzt das Serviceangebot von A&M in Deutschland
Latest insights The latest insights from Jonathan Boyers's team
Thought Leadership
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
Contact me
FOLLOW & CONNECT WITH A&M